Annovis Bio, Inc. (ANVS) Dividend History

Company News

• Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

  Annovis Bio, a late-stage clinical drug platform company, will present data from its latest Phase 3 Parkinson's disease and Phase 2/3 Alzheimer's disease studies at the AD/PD™ 2025 conference in Vienna.

  GlobeNewswire Inc.
• LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight

  LEQEMBI, an Alzheimer's disease treatment developed by Biogen and Eisai, has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. The Alzheimer's disease market is highly competitive, with numerous companies advancing therapies in the pipeline.

  GlobeNewswire Inc.

  Featured Companies: BIIB LLY SAVA
• Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight

  The article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical trials.

  GlobeNewswire Inc.

  Featured Companies: ABBV DNLI PMN PRTA
• Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

  Annovis Bio, a late-stage clinical drug platform company, announced that its CEO will present at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference, highlighting the progress of the pivotal Phase 3 trial in early Alzheimer's disease and strategic initiatives toward a New Drug Application for buntanetap.

  GlobeNewswire Inc.
• Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

  Annovis Bio Inc. has announced the start of a pivotal Phase 3 study evaluating its drug candidate buntanetap for the treatment of early Alzheimer's disease. The study aims to assess the safety and efficacy of buntanetap in improving cognition and functional ability in patients.

  GlobeNewswire Inc.